[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100601267":3},{"organization":4,"outcomesModule":7,"designInfo":53,"detailedDescription":39,"studyPopulation":39,"armGroups":59,"interventions":67,"overallOfficials":39,"centralContacts":82,"locations":91,"responsibleParty":114,"collaborators":39,"id":116,"slug":117,"hasResults":118,"nctId":119,"briefTitle":120,"officialTitle":121,"acronym":39,"eligibilityCriteria":122,"healthyVolunteers":118,"sex":123,"minAge":124,"maxAge":39,"enrollmentInfo":125,"targetDuration":39,"studyType":128,"phases":129,"briefSummary":131,"conditions":132,"keywords":134,"overallStatus":94,"whyStopped":39,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":140,"completionDateStruct":142,"leadSponsor":144,"locationsCount":145},{"fullName":5,"class":6},"GlaxoSmithKline","INDUSTRY",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":39},[9],{"measure":10,"description":11,"timeFrame":12},"Durable Response Rate for 12 months (DRR12) assessed by Blinded Independent Central Review (BICR)","DRR12 is defined as the proportion of participants with confirmed Complete Response (CR) or Partial Response (PR), and Duration of Response (DOR) lasting greater than or equal to (≥) 12 months, per Response Evaluation Criteria in Solid Tumors, version 1.1 (RECIST 1.1).","Up to approximately 148 weeks",[14,17,21,24,27,30,32,35,37,41,43,45,47,49,51],{"measure":15,"description":16,"timeFrame":12},"DRR12 assessed by Investigator","DRR12 is defined as the proportion of participants with confirmed Complete Response (CR) or Partial Response (PR), and Duration of Response (DOR) lasting greater than or equal to (≥) 12 months, per RECIST 1.1.",{"measure":18,"description":19,"timeFrame":20},"Progression-free survival (PFS) per RECIST 1.1, assessed by BICR","PFS is defined as the time from the date of first dose to the date of first documented disease progression (PD) or death due to any cause, whichever comes first.","Up to 226 weeks",{"measure":22,"description":23,"timeFrame":20},"Progression-free survival (PFS) per RECIST 1.1, assessed by investigator","PFS is defined as the time from the date of first dose to the date of first documented PD or death due to any cause, whichever comes first.",{"measure":25,"description":26,"timeFrame":20},"Overall survival (OS)","OS is defined as time from first dose of study intervention to death from any cause.",{"measure":28,"description":29,"timeFrame":20},"Overall response rate (ORR) per RECIST 1.1 assessed by BICR","ORR is defined as the proportion of participants with confirmed CR or PR.",{"measure":31,"description":29,"timeFrame":20},"ORR per RECIST 1.1 assessed by Investigator",{"measure":33,"description":34,"timeFrame":20},"Duration of response (DOR) per RECIST 1.1 assessed by BICR","DOR is defined as the time from the date of first documented objective response (confirmed CR or PR) to the date of first documented PD or death due to any cause, whichever comes first.",{"measure":36,"description":34,"timeFrame":20},"DOR per RECIST 1.1 assessed by Investigator",{"measure":38,"description":39,"timeFrame":40},"Serum concentration of dostarlimab",null,"Up to 67 weeks",{"measure":42,"description":39,"timeFrame":40},"Concentration at the end of infusion (C-EOI) for dostarlimab",{"measure":44,"description":39,"timeFrame":40},"Trough concentration (Ctrough) for dostarlimab",{"measure":46,"description":39,"timeFrame":20},"Number of participants with Anti-drug antibody (ADA) against dostarlimab",{"measure":48,"description":39,"timeFrame":20},"Number of participants with adverse events (AEs), Immune-mediated adverse events (imAEs), and serious adverse events (SAEs) by severity",{"measure":50,"description":39,"timeFrame":20},"Number of participants with AEs, imAEs, and SAEs leading to dose modifications or study intervention discontinuation",{"measure":52,"description":39,"timeFrame":20},"Number of participants with AEs leading to death",{"allocation":54,"interventionModel":55,"interventionModelDescription":39,"primaryPurpose":56,"observationalModel":39,"timePerspective":39,"maskingInfo":57},"NA","SINGLE_GROUP","TREATMENT",{"masking":58,"maskingDescription":39,"whoMasked":39},"NONE",[60],{"label":61,"type":62,"description":39,"interventionNames":63},"Dostarlimab-Carboplatin-Paclitaxel followed by Dostarlimab Monotherapy","EXPERIMENTAL",[64,65,66],"Biological: Dostarlimab","Drug: Carboplatin","Drug: Paclitaxel",[68,73,78],{"type":69,"name":70,"description":71,"armGroupLabels":72,"otherNames":39},"BIOLOGICAL","Dostarlimab","Dostarlimab will be administered.",[61],{"type":74,"name":75,"description":76,"armGroupLabels":77,"otherNames":39},"DRUG","Carboplatin","Carboplatin will be administered.",[61],{"type":74,"name":79,"description":80,"armGroupLabels":81,"otherNames":39},"Paclitaxel","Paclitaxel will be administered.",[61],[83,88],{"name":84,"role":85,"phone":86,"phoneExt":39,"email":87},"US GSK Clinical Trials Call Center","CONTACT","877-379-3718","GSKClinicalSupportHD@gsk.com",{"name":89,"role":85,"phone":90,"phoneExt":39,"email":87},"EU GSK Clinical Trials Call Center","+44 (0) 20 89904466",[92],{"facility":93,"status":94,"city":95,"state":96,"zip":97,"country":98,"countryCode":99,"cosmosGeoPoint":100,"geoPoint":105,"contacts":106},"GSK Investigational Site","RECRUITING","Jinan","Shandong","250117","China","CN",{"type":101,"coordinates":102},"Point",[103,104],116.99722,36.66833,{"lat":104,"lon":103},[107,108,111],{"name":84,"role":85,"phone":86,"phoneExt":39,"email":87},{"name":109,"role":85,"phone":110,"phoneExt":39,"email":87},"EU GSK Clinical Trials Call Centre","+44 (0) 20 8990 4466",{"name":112,"role":113,"phone":39,"phoneExt":39,"email":39},"Dapeng Li","PRINCIPAL_INVESTIGATOR",{"type":115,"investigatorFullName":39,"investigatorTitle":39,"investigatorAffiliation":39,"oldNameTitle":39,"oldOrganization":39},"SPONSOR","100601267","phase-2-a-study-of-dostarlimab-in-combination-with-carboplatin-paclitaxel-in-chinese-participants-with-primary-advanced-or-recurrent-endometrial-cancer-ec-100601267",false,"NCT07108270","A Study of Dostarlimab in Combination With Carboplatin-paclitaxel in Chinese Participants With Primary Advanced or Recurrent Endometrial Cancer (EC)","A Phase 2, Multicenter, Open-label, Single Arm Study of Dostarlimab Plus Carboplatin-paclitaxel Followed by Dostarlimab Monotherapy in Participants With dMMR\u002FMSI-H Primary Advanced or Recurrent Endometrial Cancer in China (China RUBY)","Inclusion Criteria:\n\n1. Participant has histologically or cytologically proven EC with recurrent or advanced disease.\n2. Participant has molecular subtype of defective mismatch repair (dMMR) or microsatellite instability high (MSI-H) determined by the central reference laboratory before study intervention.\n3. Participant must have primary Stage III or Stage IV disease or first recurrent EC with a low potential for cure by radiation therapy or surgery alone or in combination, and presence of at least one target lesion per RECIST 1.1 based on Investigator's assessment and meet at least 1 of the following criteria:\n\n   1. Has primary Stage III to IV disease and is naive to systemic anticancer therapy for EC;\n   2. Has first recurrent disease and is naïve to systemic anticancer therapy for EC;\n   3. Had received prior neo-adjuvant\u002Fadjuvant anticancer therapy and had a recurrence or PD ≥6 months after completing treatment (first recurrence only).\n4. Participant has adequate archive tumor tissue sample for MMR\u002FMSI status testing. If no archival tissue is available, tissue sample must be obtained before study intervention.\n5. Participant is not pregnant or breastfeeding and agrees to use a highly effective contraceptive method during the study period if a woman of childbearing potential (WOCBP).\n6. Participant has an Eastern Cooperative Oncology Group Performance status (ECOG PS) of 0 or 1.\n7. Participant has adequate organ function, as assessed by hematologic, renal, hepatic and coagulation parameters.\n\nExclusion Criteria:\n\n1. Participant has a concomitant malignancy, or participant has a prior non-endometrial invasive malignancy who has been disease-free for \\\u003C3 years or who received any active treatment in the last 3 years for that malignancy. Non-melanoma skin cancer is allowed.\n2. Participant has any medical history of interstitial lung disease or pneumonitis.\n3. Participant has cirrhosis or current unstable liver or biliary disease.\n4. Participant has known uncontrolled central nervous system metastases, carcinomatosis meningitis, or both.\n5. Participant has a diagnosis of immunodeficiency.\n6. Participant has received prior therapy with an anti- Programmed death protein 1 (PD-1), anti- Programmed death ligand 1 (PD-L1), anti- Programmed death ligand 2 (PD-L2), or anti- Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) agent.\n7. Participant has not recovered adequately from AEs.\n8. Participant has received prior anticancer therapy (chemotherapy, targeted therapies, hormonal therapy, radiotherapy, or immunotherapy) within 21 days prior to the first dose of study intervention.\n9. Participant has received any live vaccine within 30 days of the first dose of study intervention. Vaccination against coronavirus disease 2019 (COVID-19) using vaccines that are authorized via the appropriate regulatory mechanisms are not exclusionary.\n10. Participant has Hepatitis B surface antigen (HBsAg) positive, or Hepatitis C virus (HCV) Ribonucleic acid (RNA) positive at screening or within 3 months prior to the first dose of study intervention.\n11. Participant is known human immunodeficiency virus (HIV) infection.\n12. Participant is currently participating and receiving study intervention or has participated in a study of an investigational agent and received study intervention or used an investigational device within 4 weeks of the first dose of treatment.\n13. Participant with contraindication to carboplatin and paclitaxel.","FEMALE","18 Years",{"count":126,"type":127},30,"ESTIMATED","INTERVENTIONAL",[130],"PHASE2","The goal of this clinical trial is to see how well dostarlimab works when administered with the chemotherapy drugs carboplatin and paclitaxelin in treating EC in Chinese participants. The study aims to understand the treatments effectiveness, safety, how the drugs behave in the body, and whether it causes any immune reactions.",[133],"Neoplasms, Endometrial",[135,70,75,79],"Endometrial cancer","2025-12-19",{"date":138,"type":139},"2025-12-22","ACTUAL",{"date":141,"type":139},"2025-11-27",{"date":143,"type":127},"2030-03-31",{"name":5,"class":6},1]